Back
Mobileye Global, Inc. 10K Form
Sell
30
MBLY
Mobileye Global, Inc.
Last Price:
$11.84
Seasonality Move:
-6%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
| 2023-11-09 | 10Q | MBLY/Mobileye Global, Inc. Quarterly |
| 2023-08-10 | 10Q | MBLY/Mobileye Global, Inc. Quarterly |
| 2023-05-11 | 10Q | MBLY/Mobileye Global, Inc. Quarterly |
| 2022-12-07 | 10Q | MBLY/Mobileye Global, Inc. Quarterly |
Receive MBLY News And Ratings
See the #1 stock for the next 7 days that we like better than MBLY
MBLY Financial Statistics
Sales & Book Value
| Annual Sales: | $1.7B |
|---|---|
| Cash Flow: | $161.7M |
| Price / Cash Flow: | 14.98 |
| Annual Sales: | $14.67 |
| Price / Book: | 0.82 |
Profitability
| EPS (TTM): | -0.41360 |
|---|---|
| Net Income (TTM): | $-336M |
| Gross Margin: | $673M |
| Return on Equity: | -2.79% |
| Return on Assets: | -2.67% |
Mobileye Global, Inc. Earnings Forecast
Key Mobileye Global, Inc. Financial Ratios
-
The Gross Profit Margin over the past 10 years for MBLY is 40.69%.
-
The Selling, General & Administrative Expenses for MBLY have been equal to 11.37% of Gross Profit Margin.
-
The Research & Development expenses have been 65.48% of Revenue.
-
The Net Earning history of MBLY is -186.82% of Total Revenues.
-
Per Share Earnings over the last 10 years have been positive in 6 years.
Mobileye Global, Inc. Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Industry: | Automobile Components |
| Sector: | Consumer Discretionary |
| Current Symbol: | MBLY |
| CUSIP: | N51488 |
| Website: | mobileye.com |
Debt
| Debt-to-Equity Ratio: | 0 |
|---|---|
| Current Ratio: | 6.46 |
| Quick Ratio: | 5.21 |
Price-to-Earnings
| Trailing P/E Ratio: | 0 |
|---|---|
| Forward P/E Ratio: | 29.18 |
MBLY Technical Analysis vs Fundamental Analysis
Sell
30
Mobileye Global, Inc. (MBLY)
is a Sell
Is Mobileye Global, Inc. a Buy or a Sell?
-
Mobileye Global, Inc. stock is rated a SellThe current Mobileye Global, Inc. [MBLY] share price is $11.83. The Score for MBLY is 30, which is 40% below its historic median score of 50, and infers higher risk than normal.